Avalo Therapeutics, Inc. (AVTX)
Nasdaq · Healthcare · Biotechnology
$14.60−2.60%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $783M
- 52-week range
- $12.51 – $24.27
- 52-week change
- +11.20%
- EPS (trailing)
- −$4.31
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $59K (−86.62%)
- Net income
- −$78.3M
- Operating margin
- −123601.7%
- Diluted EPS
- −$5.84
From the company’s annual report on SEC EDGAR.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Headquarters: Wayne, United States · 33 employees · avalotx.com